Table of contents
In this issue
p175 | doi:10.1038/nrd1688
Editorial: Bridging the divide
p177 | doi:10.1038/nrd1678
News and Analysis
News
Vioxx fears prompt call for user fee evaluation | PDF (229 KB)
p179 | doi:10.1038/nrd1689
News
Europe supports plans for research on children | PDF (229 KB)
p180 | doi:10.1038/nrd1656
News
Share and share alike | PDF (229 KB)
p180 | doi:10.1038/nrd1683
News in Brief
Exanta's risk/benefit conundrum revealed | Crawford nominated for permanent FDA commissioner post | Pfizer to cut sales jobs? | HIV generic approved amongst a new climate of fear | Adderall risks create difference in opinion | Agreement reached over cancer vaccines | PDF (229 KB)
p181 | doi:10.1038/nrd1685
Patent watch
Beware the lexicographer rule | PDF (229 KB)
p182 | doi:10.1038/nrd1679
Patent watch
Catch 22 for generics manufacturers? | PDF (0KB)
p182 | doi:10.1038/nrd1680
Patent primer
Third-party re-examination at the US PTO | PDF (229 KB)
p183 | doi:10.1038/nrd1681
Career Path
Chris Lipinski | PDF (52 KB)
p184 | doi:10.1038/nrd1686
From the analyst's couch
Raising HDL cholesterol | PDF (105 KB)
p185 | doi:10.1038/nrd1676
Fresh from the Pipeline
Pegaptanib sodium | PDF (121 KB)
p187 | doi:10.1038/nrd1677
Research Highlights
Lead discovery: Small is beautiful | PDF (188 KB)
p190 | doi:10.1038/nrd1669
Cardiovascular disease: Viagra for broken hearts? | PDF (107 KB)
p190 | doi:10.1038/nrd1670
Drug resistance: Passing on protection | PDF (136 KB)
p191 | doi:10.1038/nrd1668
Antiviral drugs: A step ahead of drug resistance | PDF (106 KB)
p192 | doi:10.1038/nrd1671
In brief
Anticancer drugs | Computational chemistry | Neurodegenerative disease | Lead discovery | PDF (106 KB)
p192 | doi:10.1038/nrd1673
Cardiovascular disease: A dual target | PDF (87 KB)
p198 | doi:10.1038/nrd1672
Focus on: Atherothrombosis
Reviews
HDL as a target in the treatment of atherosclerotic cardiovascular disease
Patrick Linsel-Nitschke & Alan R. Tall
p193 | doi:10.1038/nrd1658
Reviews
The evolving role of natural products in drug discovery
Frank E. Koehn & Guy T. Carter
p206 | doi:10.1038/nrd1657
Therapeutic applications of polymeric artificial cells
Thomas Ming Swi Chang
p221 | doi:10.1038/nrd1659
Integrase inhibitors to treat HIV/Aids
Yves Pommier, Allison A. Johnson & Christophe Marchand
p236 | doi:10.1038/nrd1660
Perspectives
Article series: Model organisms
Innovation
Reporter mice and drug discovery and development
Adriana Maggi & Paolo Ciana
p249 | doi:10.1038/nrd1661
Innovation
Healing sound: the use of ultrasound in drug delivery and other therapeutic applications
Samir Mitragotri
p255 | doi:10.1038/nrd1662
Correspondence
Correspondence: Proteasome inhibition as an anticancer target
Constantine S. Mitsiades, Paul G. Richardson & Kenneth C. Anderson
| doi:10.1038/nrd1658-c1
Author Reply: Proteasome inhibition as an anticancer target
Irena Melnikova & James Golden
| doi:10.1038/nrd1658-c2
